z-logo
open-access-imgOpen Access
A Regulatory Role for CD37 in T Cell Proliferation
Author(s) -
Annemiek B. van Spriel,
Kirsten L. Puls,
Mariam Sofi,
Dodie Pouniotis,
Hubertus Hochrein,
Zane Orinska,
Klaus–Peter Knobeloch,
Magdalena Plebanski,
Mark D. Wright
Publication year - 2004
Publication title -
the journal of immunology/the journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.737
H-Index - 372
eISSN - 1550-6606
pISSN - 0022-1767
DOI - 10.4049/jimmunol.172.5.2953
Subject(s) - cd28 , cell growth , microbiology and biotechnology , t cell receptor , t cell , biology , cd3 , cd8 , cancer research , immunology , antigen , biochemistry , immune system
CD37 is a leukocyte-specific protein belonging to the tetraspanin superfamily. Previously thought to be predominantly a B cell molecule, CD37 is shown in this study to regulate T cell proliferation. CD37-deficient (CD37(-/-)) T cells were notably hyperproliferative in MLR, in response to Con A, or CD3-TCR engagement particularly in the absence of CD28 costimulation. Hyperproliferation was not due to differences in memory to naive T cell ratios in CD37(-/-) mice, apoptosis, or TCR down-modulation. Division cycle analyses revealed CD37(-/-) T cells to enter first division earlier than wild-type T cells. Importantly, proliferation of CD37(-/-) T cells was preceded by enhanced early IL-2 production. We hypothesized CD37 to be involved in TCR signaling and this was supported by the observation that CD4/CD8-associated p56(Lck) kinase activity was increased in CD37(-/-) T cells. Remarkably, CD37 cross-linking on human T cells transduced signals that led to complete inhibition of CD3-induced proliferation. In the presence of CD28 costimulation, CD37 engagement still significantly reduced proliferation. Taken together, these results demonstrate a regulatory role for CD37 in T cell proliferation by influencing early events of TCR signaling.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here